Another FDA 'No' For Acacia Over Unresolved Facility Deficiencies

Confusion reigns at the UK firm as a second attempt to get approval for its nausea and vomiting treatment Barhemsys floundered following an insufficient resolution of manufacturing deficiencies at the supplier of the drug.

Typewriter
More bad news for Acacia • Source: Shutterstock

Investors have lost patience with Acacia Pharma Ltd., sinking the UK firm's stock after it suffered a second rejection from the US Food and Drug Administration for the post-operative nausea and vomiting (PONV) therapy Barhemsys, once again as a result of problems at the contract drug manufacturer.

Acacia was hit with its first complete response letter from the FDA in October 2018 which identified deficiencies that had been reported during an inspection of a facility of the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Manufacturing

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: a preview of major ASCO readouts; Roivant stays patient in deals; Lilly diversifies pain pipeline with SiteOne acquisition; Nucala gets US COPD nod; and women in Indian pharma.

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By 

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By 

One Phase III trial hits but a second study misses by a mile.